Kyverna Therapeutics will implement its Ingenui-T platform into ElevateBio’s cell product manufacturing activities at its BaseCamp, Massachusetts facility.
Under the terms of the deal, of which financial details have not been disclosed, the pair have partnered to expand process development and production of Ingenui-T-derived chimeric antigen receptor (CAR) T-cell therapies.
Ingenui-T is Kyverna’s autologous CAR T-cell therapy manufacturing platform, designed to cater for autoimmune disease patients. The platform aims to advance product availability, as well as minimizing the cost of goods typically associated with personalized CAR-T cell therapy production.
DepositPhotos/maxkabakov
“We are excited by the potential to not only provide dramatic benefit to patients by eliminating the underlying disease pathology using CAR T-cell therapy, but also to bring innovation to other aspects of the patient journey,” said Karen Walker, chief technology officer at Kyverna.
“Together with ElevateBio, we aim to deliver radical benefits to patients in less time, with lower impact, and at substantially reduced cost.”
Through the implementation of Kyverna’s Ingenui-T platform at ElevateBio’s BaseCamp facility located in Waltham, Massachusetts, the collaboration aims to optimize manufacturing processes and speed up the development of its therapies.
This is not the first time ElevateBio’s BaseCamp site has agreed to provide manufacturing and technical expertise. In November 2020, the firm partnered with TCR2 Therapeutics to advance its cell therapy, TC-210. Furthermore, in September 2022, the firm signed a deal with the University of Pittsburgh to use its development and manufacturing platform, BaseCamp, to accelerate cell and gene therapies (CGTs).
BioProcess Insider spoke to chief operating officer at ElevateBio, Mike Paglia in September who said BaseCamp is backed by “the team and the know-how” that does not “only accelerate [customer] timelines but actually means [we] get it right the first time.”
Meanwhile, in August, Kyverna boosted its CAR-T pipeline by extending its Series B financing round, bringing the total of funding to $145 million. The firm said the funding will support clinical advancement of fully human anti-CD19 CAR T-cell therapies for autoimmune diseases. The company’s anti-CD19 CAR T-cell therapies KYV-101 and KYV-201 target CD19, a protein found on the surface of B cells associated with various types of autoimmune diseases including lupus nephritis.
You May Also Like
